Board considered and recommended the re-appointment of Ms. Priya Gandhi as Executive Director of the Company for the period of 3 years with effect from 28 October 2026, subject to approval ....
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences reported strong FY26 results with standalone revenue of INR 2,921.36 million (up 2% YoY) and standalone profit after tax of INR 521.00 million (up 63.7% YoY). Consolidated revenue stood at INR 3,325.99 million with consolidated PAT of INR 574.84 million, up 99.4% YoY. The Board recommended a dividend of INR 11 per share (110%) for FY26, subject to shareholder approval. Additionally, the Board approved the re-appointment of Ms. Priya Gandhi as Executive Director for 3 years from 28 October 2026. The company also completed divestment of its Texas Lifescience Private Limited subsidiary in March 2026. Statutory auditors Chandulal M. Shah & Co. issued an unmodified opinion on the financial results.
Strong profitability growth and dividend recommendation are positive signals for shareholders. The re-appointment of a promoter family member (daughter of CEO) to the board maintains leadership continuity.